Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy

Maekawa, Naoya; Konnai, Satoru; Asano, Yumie; Sajiki, Yamato; Deguchi, Takao; Okagawa, Tomohiro; Watari, Kei; Takeuchi, Hiroto; Takagi, Satoshi; Hosoya, Kenji; Kim, Sangho; Ohta, Hiroshi; Kato, Yukinari; Suzuki, Yasuhiko; Shiro, Motoo; Ohashi, Kazuhiko

doi:10.1038/s41598-022-13484-8

Cited by 12 publications

(13 citation statements)

References 64 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, canine models can be used as representative models of human melanoma, especially in the development of next-generation therapies 103 . These reports suggest that canine melanoma may be particularly sensitive to checkpoint inhibitory antibodies or other immunotherapeutic modalities as they become available, which may reflect the success of such agents in melanoma therapy in humans 103,104 .…”

Section: Melanomamentioning

confidence: 99%

Comparative oncology: overcoming human cancer through companion animal studies

Cho

2023

Exp Mol Med

View full text Add to dashboard Cite

Comparative oncology is a field of study that has been recently adopted for studying cancer and developing cancer therapies. Companion animals such as dogs can be used to evaluate novel biomarkers or anticancer targets before clinical translation. Thus, the value of canine models is increasing, and numerous studies have been conducted to analyze similarities and differences between many types of spontaneously occurring cancers in canines and humans. A growing number of canine cancer models as well as research-grade reagents for these models are becoming available, leading to substantial growth in comparative oncology research spanning from basic science to clinical trials. In this review, we summarize comparative oncology studies that have been conducted on the molecular landscape of various canine cancers and highlight the importance of the integration of comparative biology into cancer research.

show abstract

Section: Melanomamentioning

confidence: 99%

Comparative oncology: overcoming human cancer through companion animal studies

Cho

2023

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…Prognostic biomarkers of response were similarly investigated in a trial treating dogs with oral malignant melanoma using checkpoint blockade (39). The Ohashi Laboratory pioneered PD-L1 antibody therapy in dogs and have completed two clinical trials to date (40)(41)(42).…”

Section: Nk Cells In Canine Immunotherapymentioning

confidence: 99%

Improved characterization and translation of NK cells for canine immunotherapy

Razmara,

Gingrich,

Toedebusch

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

The field of cancer immunology has seen a meteoric rise in interest and application due to the discovery of immunotherapies that target immune cells, often leading to dramatic anti-tumor effects. However, successful cellular immunotherapy for solid tumors remains a challenge, and the application of immunotherapy to dogs with naturally occurring cancers has emerged as a high yield large animal model to bridge the bench-to-bedside challenges of immunotherapies, including those based on natural killer (NK) cells. Here, we review recent developments in the characterization and understanding of canine NK cells, a critical springboard for future translational NK immunotherapy research. The characterization of canine NK cells is exceptionally pertinent given the ongoing challenges in defining them and contextualizing their similarities and differences compared to human and murine NK cells compounded by the limited availability of validated canine specific reagents. Additionally, we summarize the current landscape of the clinical and translational literature employing strategies to capitalize on endogenous and exogenous NK cell immunotherapy in canine cancer patients. The insights regarding efficacy and immune correlates from these trials provide a solid foundation to design and test novel combinational therapies to enhance NK cell activity with the added benefit of motivating comparative work to translate these findings to human cancers with extensive similarities to their canine counterparts. The compilation of knowledge from basic canine NK phenotype and function to applications in first-in-dog clinical trials will support the canine cancer model and enhance translational work to improve cancer outcomes for both dogs and humans.

show abstract

“…Participant numbers were limited, but preliminary evidence also suggested a potential benefit to treatment with canonized anti PD-1 antibodies [ 96 ]. Studies with anti-PD-L1 antibodies suggest limited clinical benefit [ 98 , 99 ]. A caninized anti-CTLA-4 has also been developed and has been shown to enhance in vitro T-cell function [ 70 ].…”

Section: Humanized Monoclonal Antibodiesmentioning

confidence: 99%

Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology

Hambly,

Ruby,

Mourich

et al. 2023

Veterinary Sciences

View full text Add to dashboard Cite

The emergence of immunotherapy for the treatment of human cancers has heralded a new era in oncology, one that is making its way into the veterinary clinic. As the immune system of many animal species commonly seen by veterinarians is similar to humans, there is great hope for the translation of human therapies into veterinary oncology. The simplest approach for veterinarians would be to adopt existing reagents that have been developed for human medicine, due to the potential of reduced cost and the time it takes to develop a new drug. However, this strategy may not always prove to be effective and safe with regard to certain drug platforms. Here, we review current therapeutic strategies that could exploit human reagents in veterinary medicine and also those therapies which may prove detrimental when human-specific biological molecules are used in veterinary oncology. In keeping with a One Health framework, we also discuss the potential use of single-domain antibodies (sdAbs) derived from camelid species (also known as Nanobodies™) for therapies targeting multiple veterinary animal patients without the need for species-specific reformulation. Such reagents would not only benefit the health of our veterinary species but could also guide human medicine by studying the effects of outbred animals that develop spontaneous tumors, a more relevant model of human diseases compared to traditional laboratory rodent models.

show abstract

Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy

Cited by 12 publications

References 64 publications

Comparative oncology: overcoming human cancer through companion animal studies

Comparative oncology: overcoming human cancer through companion animal studies

Improved characterization and translation of NK cells for canine immunotherapy

Potential Promises and Perils of Human Biological Treatments for Immunotherapy in Veterinary Oncology

Contact Info

Product

Resources

About